What Happened?
New York, NY-based Stelexis-Therapeutics Appointed Patrick Doyle as Chief Executive Officer
About the Company
Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
About the Person
Patrick Doyle is Chief Executive Officer at Stelexis Therapeutics. Previously, Patrick held various senior HR leadership roles in the industry.
Info Source
News
Short Profile